Share Name Share Symbol Market Type Share ISIN Share Description
Aortech International Plc LSE:AOR London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 71.50 15,700 01:00:00
Bid Price Offer Price High Price Low Price Open Price
68.00 75.00 71.50 71.50 71.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.46 -0.63 -4.72 11
Last Trade Time Trade Type Trade Size Trade Price Currency
08:02:00 O 7,000 74.00 GBX

Aortech (AOR) Latest News

More Aortech News
Aortech Takeover Rumours

Aortech (AOR) Share Charts

1 Year Aortech Chart

1 Year Aortech Chart

1 Month Aortech Chart

1 Month Aortech Chart

Intraday Aortech Chart

Intraday Aortech Chart

Aortech (AOR) Discussions and Chat

Aortech (AOR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
07:02:0274.007,0005,180.00O
07:00:1970.028,7006,091.74O
2019-10-21 15:31:0374.002,6661,972.84O
2019-10-21 14:15:2070.05700490.35O
2019-10-21 13:58:5272.002,5001,800.00O
View all Aortech trades in real-time

Aortech (AOR) Top Chat Posts

DateSubject
21/10/2019
09:20
Aortech Daily Update: Aortech International Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker AOR. The last closing price for Aortech was 71.50p.
Aortech International Plc has a 4 week average price of 43.50p and a 12 week average price of 43.50p.
The 1 year high share price is 78.50p while the 1 year low share price is currently 41.50p.
There are currently 14,686,608 shares in issue and the average daily traded volume is 22,259 shares. The market capitalisation of Aortech International Plc is £10,500,924.72.
21/10/2019
20:15
bones: Thankfully, the AOR board is not the type to attempt to hype the share price with fatuous RNS releases. It may well be that the industry chatter we are hearing of will do the bidding for us in the meantime! The Biomerics tweet is a case in point as well as the information exchanged among the industry leaders at the recent Lisbon event. Personally speaking, I would like to see the market re-rate the share price so that it reflects the promise and then we can have an update later when something of substance arises.
11/10/2019
08:55
coolhandfluke: I believe there is more than enough good news in this update to underpin a re-rating of the share price.
10/10/2019
17:36
landy90: There were more sellers than buyers as Miton off loaded 860,000 shares. Strange that the Chairman of the QCA cant issue a TR1. Overhang must be gone now so hope any announcements move the share price to a level that at least gives some credit for the value. Remember in 2016, Foldax got $3m for 18% of the company - post money - $17m. With AOR at £8m, over £2m cash in the bank, a polymer licensing business and the patches and grafts, AIM is giving no value to the Heart Valve.Why be public I ask?
04/9/2019
11:20
cfb2: Yes, momentum traders. Probably means some share price volatility for a while.
23/8/2019
10:56
bones: Thanks Brucie5. Bill Brown also said he was unhappy with the share price but that it is not his duty to issue RNS’s merely to support it. They will only advise the market when it is right to do so. As John Ely said, take care of the patient and the shareholders will be taken care of (to paraphrase).
10/7/2019
14:57
bones: A phenomenon I have noted in several small shares lately is for punters (no other word applies) to buy a chunk only to sell the lot, sometimes the same day and sometimes a day or two later, almost always at a loss. The raison d’etre seems to be that the purchase either creates or follows momentum following which a quick profit can be grabbed for a few points. Yet, usually, that never happens. I find it hard to believe that the person who bought 30,000 AOR two days ago at 60p would be the same as the one who has dumped the same amount today at 58.2p. The spread has been a killer lately due to illiquidity. I don’t rule it out though given the desperate gamblers that seem to be present in our markets. Investors are the silent majority I guess. Anyone want to own up? :) As CHF says, the net effect of the two trades is a share price up by 5p, so the sale today was easily absorbed. It’s not really a surprise given how oversold the share was on the RSI reading (at under 10 which is stupidly low).
12/6/2019
17:33
bones: Well, we know Miton decreased to around 6% from 9% but they sold a lot of stock across the board when they were hit for redemptions after AIM crashed late last year (a mini version of Woodford you might say!). WB is well up around 16% but they are just nominees for PI’s on the whole. Problem for AOR is they are too small to attract proper institutions currently so the share price is subject to the mood swings of PI’s. Fortunately, I think most of those invested are sticky and sane types :) All the signs are that the second half of 2019 should see more activity in AOR as prototyping, manufacturing and testing takes place ahead of the hoped for CE Marks on the grafts and patches. Anything to do with progress on the heart valve is all “bunce” as far as I am concerned. The pot of gold lies somewhere over yonder!
05/6/2019
16:57
coolhandfluke: Hi Bones,My take on AOR at the moment is that people are trading this share. Notwithstanding news that would move the share price in a positive way , hopefully, traders are loading up between 50 and 60p moving the price up, then selling between 70and 80p bringing the price back down. So until we move to the next development level, expect to move between 50 and 80p.CheersCHF
09/1/2019
20:19
bones: To pass the time, I've been doing a bit of digging in Companies House on a few companies of interest to me (not just AOR). I found an intriguing development on AOR, albeit purely administrative: As of last week, the Company Secretary role (which is a legally important appointed officer role that requires disclosure at Companies House) changed at Aortech International plc and its subsidiaries. The new Company Secretary is now a lady called Kathryn Full. She has one other Company Secretary role disclosed at Companies House and that is and remains Co Sec (since 2010) for Vascular Flow Technologies Ltd ("VFT"), the company that AOR has appointed to do all of its work on the heart valve development following the fund raising in June 18. The previous Co Secretary was based at the AOR Surrey HQ which makes me speculate that they might close those offices (?) seeing as they seem to have no geographical purpose now that all the action is in Scotland (and the USA where John Ely, the non-exec director and heart valve expert for AOR resides, as does Biomerics LLC, AOR's contract polymer manufacturer). VFT is essentially an R&D company these days. It makes very little turnover yet, over the years, has burned through £20M if I read the accounts correctly, some of it financed from offshore investors. There was a $10m financing round in 2016 which cleared out some previous investor loans. Clearly though, the cutting edge work they are doing on blood flow computer simulation (from which AOR hope to benefit) has massive potential. VFT's private shareholder structure seems convoluted, not surprising I guess. The investors there must be impressed as they keep topping up to finance the progress. Anyway, my interest has been piqued by this change of Co Sec at AOR. It seems to be somehow significant that they have taken on the person from their R&D partner, VFT which is independent in all other respects, with its own customers. Perhaps the thinking was simply the need to have someone based in Scotland and that this person came highly recommended. Perhaps it was a requirement of Scottish Enterprise to have Scottish officers and offices? Maybe there is more to the relationship going forward between AOR and VFT? I am merely thinking and speculating aloud but think it is of interest, especially as I have a decent-sized personal interest in the quoted shares of AOR and information is not readily made available as the share price shoots all over the shop!
15/6/2018
23:49
bones: INTRODUCTION AorTech International plc holds patents, know-how and trade secrets relating to a family of bio-compatible materials. A large range of polymers has been developed within the Elast-Eon(TM) family with different mechanical properties, such as hardness and elasticity. With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510ks, CE Marks, Australian TGA and Japanese Ministry of Health approvals. COMPANY WEBSITE: hTTps://www.aortech.net/ BACKGROUND After several years of under-performance, containing more than its fair share of failed strategies and legal disputes with customers, partners and an ex-CEO (settled amicably in December 2017 for an undisclosed sum paid to AOR), Aortech is finally clear for take off! A new strategy for the company, incorporating the benefits of its long held, valuable IP assets, has finally been revealed (in May 2018); new investors have been rounded up to join the patient ones and top personnel have been recruited. Fresh money is in the bank ready to exploit the new frontiers in cardiovascular medical devices and cosmetic implants. SOME STATS Market capitalisation (June 18) = GBP 6 MILLION Cash in bank (June 18) = GBP 3 MILLION Invested in current proven technology to date = GBP 60 MILLION (including GBP 30 MILLION in heart valve R&D) Partnered with Vascular Flow Technologies for their Spiral Laminar Flow (TM) blood flow technology - see htTps://vascular-flow.com/our-technology/ . VFT appear (from reading their accounts) to have invested ï¿&frac12;20M into this over several years, so AorTech is leveraging this R&D for a fraction of the cost. STRATEGY Aortech is now seeking to maximise value from its IP portfolio by developing certain products while maintaining what the directors believe to be a low cost/risk business model. As part of this strategy, the company is entering into a development and manufacturing agreement with RUA Medical - click here hTTp://www.ruamedical.com - a medical textiles manufacturer, and a development contract with Vascular Flow Technologies - click here hTTp://vascular-flow.com - a medical device development company. If successfully developed and approved by the relevant regulatory authorities, the company proposes to employ a lean sales and marketing strategy for its products, a distribution model to provide access to hospital markets and OEM sales of devices to other medical device companies. Initial product pipeline is to be: 1. Cardiovascular and soft tissue patches 2. Large bore grafts 3. Synthetic heart valve Three new non-executive directors have been recruited, two of whom are from the highest echelons of the cardiovascular world! John Ely (NED - Heart Valve Expert) Geoffrey Berg (NED - Cardiovascular Expert) See this RNS and Offer document for all the details about these products and new directors: hTTps://uk.advfn.com/stock-market/london/aortech-AOR/share-news/AorTech-International-PLC-Conditional-Placing-and/77473499 hTTps://www.aortech.net/wp-content/uploads/2018/05/249297-Project-Amplify-Circular-WEB.pdf AORTECH IN THE PRESS Essential introduction here (Scottish Herald 7th July 2018): hTTp://www.heraldscotland.com/business_hq/16339604.heart-valve-pioneer-aortech-international-returns-to-its-scottish-roots/ Video Interview with John McKenna, AOR director (CTSNet.org 6th December 2018): hTTp://www.ctsnet.org/article/pioneers-cardiac-surgery-john-mckenna Interactive Investor website - Five AIM growth shares for your 2019 ISA (ii.co.uk 1st March 2019) hTTps://www.ii.co.uk/analysis-commentary/five-aim-growth-shares-your-2019-isa-ii507804 INTRO VIDEO ABOUT AORTECH'S HEART VALVE Aortech acquired the original IP from CSIRO in the early 2000's - click this link hTTps://csiropedia.csiro.au/elast-eon-biocompatible-polyurethane/. Now AOR is finally funded to complete stage one of the quest to commercialise the holy grail that is the synthetic heart valve. This video is the basic introduction to the technology (note the reference to Aortech in it). !YOUTUBEVIDEO:qfzXvuh2xxc: THE DISRUPTIVENESS OF POLYMER HEART VALVES To gain an idea of how AOR is standing on the cusp of a disruptive change to a huge industry, please refer to the following posts by Landy90 who has some knowledge of the cardiovascular industry: 2383, 2385, 2390, 2394, 2398, 2399 As always, BB posts are opinion only, so always do your own research! DIRECTOR EMI OPTIONS VEST WHEN SHARE PRICE REACHES 300p On page 46 of the Open Offer document (May 2018), the following is found: As regards options to be granted to any Director, such options will vest as to 20 per cent. after the expiry of 3 years from the date of grant, 30 per cent. on the receipt by the Company of a CE Mark for any of its products and 50 per cent. on the closing middle market quotation of the Ordinary Shares, as derived from AIM Appendix to the Daily Official List of the London Stock Exchange, being at least GBP 3.00, being 10 times the Issue Price, for 10 consecutive days on which trading takes place on AIM. BROKER NOTE 400p INITIAL TARGET PRICE Stockdale Securities' report can be accessed via Research Tree but you have to sign up, albeit there is a free 7 day trial (with your payment details): hTTps://www.research-tree.com/companies/uk/medical-equipment-services/aortech-international/research/stockdale-securities/new-projects-to-drive-shareholder-value/ae347ba2-3cc8-47d7-8789-96d2eb7972f5 Excerpt: BROKER NOTE UPDATE 21/2/19 RETAINING 400p TARGET PRICE Stockdale Securities issued a new comment in Feb19 about an industry development on polymeric heart valves that have a direct read through to Aortech's business strategy. The following is their executive summary: "We view positively the news earlier this week that the FDA has granted Foldax Inc. investigative device exemption (IDE) approval for an Early Feasibility Study of its Tria surgical aortic heart valve to treat aortic valve disease. This is because it sets the path to commerciality for AorTech with its polymeric heart valve, which uses its patented Elast-Eon polymer. With milestones set to be achieved in both the heart valve and textiles projects in 2019 and 2020, we expect to see a significant increase in news flow. We retain our 400p TP and Buy rating." TRADING UPDATE 11th OCTOBER 2019 Highlights: “...it is pleasing to report that, despite funding the R&D efforts over the six months to 30 September 2019, cash was maintained at GBP2.3 million...” “...With the progress being made with our partners...the Board decided to accelerate our recruitment plans for further in-house expertise...part funded by Scottish Enterprise...” “...Our partner, RUA Medical, has recently completed the construction and fit out of two new clean rooms that will be used to manufacture AorTech's vascular grafts and soft tissue patches...” “...A novel coating technology has been identified and trialled. We anticipate having crimped and coated prototypes in the next 6 to 8 weeks...” “...we had the opportunity to meet not only leading surgeons, but with major medical device companies and key distributors...and we are very much encouraged by the commercial opportunities that will arise once we have regulatory approvals...” “...Substantial progress has been made over recent months on the design of the polymeric heart valve...A design for manufacture (DFM) project currently underway to develop the tooling that will allow a highly consistent valve to be made both faster and cheaper...” “...a regulatory pathway has now been established for polymeric valves and testing protocols agreed. This provides us with confidence that our valve will have similar success, especially as a result of the recent improvements in design...” FINAL RESULTS 17th JULY 2019 Much of the commentary has been covered in past releases so I show here just the Outlook by Chairman Bill Brown: Outlook "The new and existing shareholders who supported the equity fundraising during the year have enabled AorTech to make significant progress over the past year and I thank those supporters for the trust placed in the business plan and the new Board of Directors. Developing new medical devices is not a short term process for either the engineers and clinicians involved or the providers of capital." "Progress has been good over the past year with no change in our expectations of the timelines to having products ready for seeking regulatory approval. I expect the current year to reach a number of milestones in the development of the polymeric heart valve, tissue patches and the large bore vascular grafts with the planning, product design and preparation for manufacturing allowing prototypes to be manufactured and trials commencing". TRADING UPDATE 14th MAY 2019 Excerpts: Our strategy of transitioning AorTech into a medical device manufacturer is progressing well with much having been achieved over the last year. The business model of working with partners means that progress has been made on a highly cost effective basis. We remain confident of delivering further progress in the current year. The development focus has been on heart valve design and the synthesising of materials for vascular prothesis. This phase is now nearing completion. Prototyping, manufacturing and testing will become the Company's principal focus over the coming year. Much technical planning has been undertaken as part of the design for manufacture process to identify the most up to date equipment available to automate and ensure repeatability of the manufacturing processes. Our team has identified an opportunity to significantly improve the way the heart valves are manufactured and, if successful, should allow optimised polymer heart valve designs to be manufactured with reduced costs. RNS UPDATE 24th JANUARY 2019 Excerpts: Heart Valve Project AorTech's novel "Leaflet Builder" software utilising Computational Fluid Dynamics has been completed and has successfully replicated, not just the leaflet design described in AorTech's patents, but has also accommodated any correction factors required to simulate the last design iteration of the AorTech valve. Work has now started on planning the future manufacturing process with the objective of designing a process, and specifying the machinery required, to manufacture valves of a consistently high quality and by a process that is verifiable from a regulatory perspective that minimises manufacturing costs and will be scalable to allow commercial volumes to be produced. Textile Projects Our partners at RUA Medical have successfully manufactured yarn which has been specifically designed for both our patch and grafts products. The yarn has now been converted into textile and the initial results have been very encouraging and more than meet our initial expectations. AorTech believes that the process of designing the yarn and textile for specific use, rather than designing a graft around existing yarn technology, is a major improvement in graft development and, as such, the new products will represent a major improvement over technology currently available in the market. Patent Issue AorTech is pleased to announce that the US Patent and Trademark Office has issued notice that Patent Number 10,195,834 entitled "BONDING PROCESS" will be issued on 5 February 2019. The invention relates to a process for bonding a silicone or silicone-based material to a polyurethane and use of the bonded silicone-polyurethane in the manufacture of biomaterials, devices, articles or implants, in particular long term implantable medical devices. RNS UPDATE 22nd NOVEMBER 2018 Interim Results We have also made good progress in confirming both market need and interest in our products. At a recent European Cardiothoracic meeting of some 3,000 surgeons and industry players, we engaged with a number of parties, including key surgeons, large industry players and product distributors, and explained which products AorTech would be bringing to the market. Feedback was very positive and the market need was confirmed for both the valve and polymer coated textile products. https://uk.advfn.com/stock-market/london/aortech-AOR/share-news/AorTech-International-PLC-Interim-Results/78740355 RNS UPDATE 23rd AUGUST 2018 AGM Statement Excerpts: "On the heart valve project, technology transfer has been completed with Vascular Flow Technologies Limited ("VFT") which is now actively engaged with John Ely.....on design optimisation." "The textile-based products are also on track with RUA Medical, in association with our polymer manufacturing partner, Biomerics Inc., and have now identified the optimal version of Elast-Eon(TM) to provide the patches and grafts with the required properties." "The polymer licensing business is performing to plan and continues to meet the Board's expectations." "We are also delighted to have been informed that the US Patent and Trademark Office will issue US Patent Number 10,059,807 on a new AorTech patent entitled GELS further building on our family of biostable materials." Overall, we are delighted with how the business is progressing and look forward to the future with confidence." RNS UPDATE 4th JULY 2018 New Patent Issued Excerpt: AorTech is pleased to announce that the Brazilian Patent Office has recently granted Patent Number PI 0711694-2 entitled Biostable Gels. The invention relates to biostable gels, the processes for their preparation and their use in the manufacture and repair of biomaterials and medical devices or implants, in particular soft tissue implants such as breast implants. Bill Brown, Chairman of AorTech said: "The issue of this patent further expands AorTech's patent portfolio, particularly in the area of breast implants. Brazil is one of the largest markets for breast enhancement outside of the USA and is therefore an important patent territory. The portfolio of IP relating to Breast Implants is not currently licensed by AorTech." RNS UPDATE 28th JUNE 2018 Development and Supply Agreement with RUA Medical Excerpt: AorTech has appointed RUA Medical as its development and manufacturing partner to bring the immediate opportunities from this platform technology to market. Bill Brown, Chairman of AorTech said: "In anticipation of entering into this agreement, the AorTech and RUA Medical teams have gone through a detailed project planning process. This process has confirmed to AorTech that RUA Medical is the ideal partner for this project and that its unique combination of R&D, project management, regulatory and manufacturing expertise should help us deliver the soft tissue pericardial patches and large bore grafts to market in a highly efficient manner." Caroline Stretton, Chief Executive Officer of RUA Medical said: "The team at RUA Medical is delighted to be partnering with AorTech on the development and supply of their transformational devices. Superior safety and performance, in conjunction with secure supply, will afford spectacular improvements to the quality of life of end users. RUA Medical also recognises the exciting future prospect of exploiting further medical device opportunities within AorTech's novel platform technology." RNS UPDATE 26th JUNE 2018 New Patent Issued Excerpt: AorTech is pleased to announce that the US Patent Office has recently granted Patent Number 9,994,668 entitled "BIOSTABLE POLYURETHANES". The invention relates to polyurethanes and processes for their preparation. The polyurethanes are biostable, creep resistant, acid resistant and abrasion resistant which makes them useful in the manufacture of biomaterials and medical devices, articles or implants, in particular, long term implantable medical devices in the fields of cardiology, orthopaedics, plastic surgery and gastroenterology. Bill Brown, Chairman of AorTech said: "We are delighted that this US Patent has been issued extending further AorTech's world class portfolio of biostable polymers for medical device use." RNS UPDATE 19th JUNE 2018 Development Agreement signed with Vascular Flow Technologies Limited ("VFT") Excerpt: Bill Brown, Chairman of AorTech, said: "In partnering with the team at VFT, AorTech now has access to Europe's leading experts in the combined field of medical imaging, guided Finite Element Analysis and Computational Fluid Dynamics. Combining the design history with this ground breaking imaging analysis should much improve the quality of the product design, reliability and performance." Craig Dunlop, General Manager and Director of VFT, said: "The team at VFT has been very impressed with the quantity and quality of data that AorTech has been able to demonstrate to us. We are very excited to be a key partner in the development of the next generation of prosthetic heart valves which should represent not only a step change in performance, but dramatically reduce the cost to manufacture these life enhancing devices." SIGNIFICANT SHAREHOLDERS ( > 3% ) AS AT 11th OCTOBER 2019 - movement in italics since 16/4/19 21.47% Walker Crips Stockbrokers (3,153,452) - increase of 5.09% 5.96% Mr Clive Titcomb (875,000) - increase of 0.72% 5.33% A J Bell Securities (782,838) - first time on 3% list 4.53% Mr JD Abell (665,308) - increase of 0.83% 4.37% Mr Gordon Wright (641,645) - unchanged 4.29% Hargreaves Lansdown Asset Management (630,367) - decrease of 0.31% 3.95% Charles Stanley (580,672) - first time on 3% list 3.68% Share Centre Investment Management (540,404) - decrease of 0.31% 3.45% Mr Bill Brown (506,649) - unchanged 3.40% Halifax Share Dealing (499,882) - first time on 3% list 3.15% Interactive Investor (463,282) - decrease of 0.31% 3.02% Barclays Wealth (443,542) - first time on 3% list 66.60% Sub Total 33.40% Shareholders < 3% 100.00% Total No longer on list = Miton Asset Management (862,071 shares all sold by Sep 19, I am reliably informed)
Aortech share price data is direct from the London Stock Exchange
Your Recent History
LSE
AOR
Aortech
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191022 07:19:58